Unknown PHASE2 INTERVENTIONAL 1-arm NCT02071069

Efficacy and Tolerance of Maintenance Therapy in Patients With Incurable Advanced Colorectal Cancer

Efficacy and Tolerance of Cetuximab Combined With Irinotecan or Fluorouracil as Maintenance Therapy in Patients With RAS-wild-type Incurable Advanced Colorectal Cancer （Confirm Study）

Sponsor: Tianshu Liu

Conditions Incurable Colorectal Cancer RAS-wild-type

Interventions Cetuximab fluorouracil irinotecan

Updated 7 times since 2017 Last updated: Nov 17, 2015 Started: Jul 31, 2013 Primary completion: May 31, 2016 Completion: Jul 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Incurable Colorectal Cancer and RAS-wild-type, this trial is ongoing. The trial is conducted by Tianshu Liu and has accumulated 7 data snapshots since 2013. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE2
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE2
Feb 2018 — Jun 2018 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 2 earlier versions

Feb 2017 — Feb 2018 [monthly]

Recruiting PHASE2
Jan 2017 — Feb 2017 [monthly]

Recruiting PHASE2

First recorded

Jul 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Tianshu Liu

Data source: Shanghai Zhongshan Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China